We acknowledge that our observation of differential time-based response of PI3K/Akt/mTOR and MAPK/ERK is on a relatively small number of patients (n = 15), and tumor biopsies collected at early and late time-points were not obtained from the same patients; further prospective study with collection of serial tumor biopsies (e.g., pretreatment, 9-days and 21-days post-treatment) from the same patients of a large-sized cohort is warranted to further confirm the current findings. This evidence concerns the gene PIK3CA and neoplasm.